Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer

A. R. Hartman, G. F. Fleming, J. J. Dillon

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Conflicting results have been published regarding the efficacy of adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy in postmenopausal, estrogen receptor (ER)-positive women. The Oxford overview suggests real but limited benefit of any chemotherapy in this group of patients but avoids analyzing smaller subsets. We wished to better quantitate the benefit of adding CMF to tamoxifen in postmenopausal ER-positive women with tumor involvement of axillary lymph nodes. Six randomized studies comparing CMF plus tamoxifen to tamoxifen alone in postmenopausal, ER-positive, node-positive women have been published since 1992. They include 2368 patients. We performed a meta-analysis of 6 endpoints: survival, disease-free survival, locoregional recurrence, distant recurrence, contralateral breast recurrence, and thromboembolic complications. There was a statistically significant increase in disease-free survival from the addition of CMF-type chemotherapy to tamoxifen in this population; the absolute risk of relapse was reduced by 5.5% at 5 years. Effects of loco-regional recurrence were greater than those on overall recurrence. No significant survival benefit was observed.

Original languageEnglish (US)
Pages (from-to)138-143
Number of pages6
JournalClinical Breast Cancer
Volume2
Issue number2
StatePublished - 2001
Externally publishedYes

Fingerprint

Methotrexate
Fluorouracil
Estrogen Receptors
Cyclophosphamide
Meta-Analysis
Tamoxifen
Breast Neoplasms
Recurrence
Drug Therapy
Disease-Free Survival
Survival
Breast
Lymph Nodes
Population
Neoplasms

Keywords

  • Chemotherapy
  • CMF
  • Estrogen receptor
  • Meta-analysis
  • Postmenopausal women
  • Tamoxifren

ASJC Scopus subject areas

  • Cancer Research

Cite this

Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer. / Hartman, A. R.; Fleming, G. F.; Dillon, J. J.

In: Clinical Breast Cancer, Vol. 2, No. 2, 2001, p. 138-143.

Research output: Contribution to journalArticle

@article{b1f7415c90794a7c9910ec7fb041da10,
title = "Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer",
abstract = "Conflicting results have been published regarding the efficacy of adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy in postmenopausal, estrogen receptor (ER)-positive women. The Oxford overview suggests real but limited benefit of any chemotherapy in this group of patients but avoids analyzing smaller subsets. We wished to better quantitate the benefit of adding CMF to tamoxifen in postmenopausal ER-positive women with tumor involvement of axillary lymph nodes. Six randomized studies comparing CMF plus tamoxifen to tamoxifen alone in postmenopausal, ER-positive, node-positive women have been published since 1992. They include 2368 patients. We performed a meta-analysis of 6 endpoints: survival, disease-free survival, locoregional recurrence, distant recurrence, contralateral breast recurrence, and thromboembolic complications. There was a statistically significant increase in disease-free survival from the addition of CMF-type chemotherapy to tamoxifen in this population; the absolute risk of relapse was reduced by 5.5{\%} at 5 years. Effects of loco-regional recurrence were greater than those on overall recurrence. No significant survival benefit was observed.",
keywords = "Chemotherapy, CMF, Estrogen receptor, Meta-analysis, Postmenopausal women, Tamoxifren",
author = "Hartman, {A. R.} and Fleming, {G. F.} and Dillon, {J. J.}",
year = "2001",
language = "English (US)",
volume = "2",
pages = "138--143",
journal = "Clinical Breast Cancer",
issn = "1526-8209",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Meta-analysis of adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy in postmenopausal women with estrogen receptor-positive, node-positive breast cancer

AU - Hartman, A. R.

AU - Fleming, G. F.

AU - Dillon, J. J.

PY - 2001

Y1 - 2001

N2 - Conflicting results have been published regarding the efficacy of adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy in postmenopausal, estrogen receptor (ER)-positive women. The Oxford overview suggests real but limited benefit of any chemotherapy in this group of patients but avoids analyzing smaller subsets. We wished to better quantitate the benefit of adding CMF to tamoxifen in postmenopausal ER-positive women with tumor involvement of axillary lymph nodes. Six randomized studies comparing CMF plus tamoxifen to tamoxifen alone in postmenopausal, ER-positive, node-positive women have been published since 1992. They include 2368 patients. We performed a meta-analysis of 6 endpoints: survival, disease-free survival, locoregional recurrence, distant recurrence, contralateral breast recurrence, and thromboembolic complications. There was a statistically significant increase in disease-free survival from the addition of CMF-type chemotherapy to tamoxifen in this population; the absolute risk of relapse was reduced by 5.5% at 5 years. Effects of loco-regional recurrence were greater than those on overall recurrence. No significant survival benefit was observed.

AB - Conflicting results have been published regarding the efficacy of adjuvant cyclophosphamide/methotrexate/5-fluorouracil (CMF)-type chemotherapy in postmenopausal, estrogen receptor (ER)-positive women. The Oxford overview suggests real but limited benefit of any chemotherapy in this group of patients but avoids analyzing smaller subsets. We wished to better quantitate the benefit of adding CMF to tamoxifen in postmenopausal ER-positive women with tumor involvement of axillary lymph nodes. Six randomized studies comparing CMF plus tamoxifen to tamoxifen alone in postmenopausal, ER-positive, node-positive women have been published since 1992. They include 2368 patients. We performed a meta-analysis of 6 endpoints: survival, disease-free survival, locoregional recurrence, distant recurrence, contralateral breast recurrence, and thromboembolic complications. There was a statistically significant increase in disease-free survival from the addition of CMF-type chemotherapy to tamoxifen in this population; the absolute risk of relapse was reduced by 5.5% at 5 years. Effects of loco-regional recurrence were greater than those on overall recurrence. No significant survival benefit was observed.

KW - Chemotherapy

KW - CMF

KW - Estrogen receptor

KW - Meta-analysis

KW - Postmenopausal women

KW - Tamoxifren

UR - http://www.scopus.com/inward/record.url?scp=0034889229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034889229&partnerID=8YFLogxK

M3 - Article

C2 - 11899785

AN - SCOPUS:0034889229

VL - 2

SP - 138

EP - 143

JO - Clinical Breast Cancer

JF - Clinical Breast Cancer

SN - 1526-8209

IS - 2

ER -